Decipher Molecular Test Could Help Identify Prostate Cancer Treatment
“For men with very high-risk prostate cancer, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference,” Sarah Howlett told Healthcare Today.
A tissue-based molecular test used in the STAMPEDE clinical trial helped researchers identify which patients benefit from abiraterone treatment, Healthcare Today reported. The UCL-led trial showed that adding abiraterone to standard hormone therapy for high-risk, localised prostate cancer can halve the risk of death and slow overall disease progression.
- A molecular test called Decipher helped identify patients who benefit from abiraterone treatment in the STAMPEDE trial.
- Researchers analyzed Decipher scores from 27,607 real-world cases and 401 randomized trial patients.
- Higher Decipher scores consistently correlated with worse outcomes, including increased risks of metastasis and death.
Higher Decipher Scores Predict Metastasis and Death Risks
Researchers analyzed Decipher scores from two datasets, including real-world patient data of 27,607 cases and 401 men with non-metastatic prostate cancer in the STAMPEDE trial, Healthcare Today reported. Higher scores consistently predicted worse outcomes for patients.
Based on reporting by Healthcare Today, data showed an adjusted hazard ratio of 1.49 for distant metastasis and 1.38 for prostate cancer mortality with every 0.1 rise in the score. Howlett noted that genomic testing could help personalize treatment decisions.
Men with high-risk disease but low Decipher scores experienced low rates of cancer spread and could potentially avoid intensive treatment, while those with high scores would be prioritized for it, Healthcare Today reported. The findings appeared in both a large real-world dataset and a randomized trial, but further validation in other datasets is required before routine clinical use.
AI Doctor Launch in Wales
A charity in Wales launched the first AI prostate doctor in the UK to help thousands of men seeking symptom information or risk guidance, Healthcare Today reported. Prostate Cymru developed the tool, noting it operates beyond a standard chatbot.

“It has been rigorously trained on current guidelines from NICE, NHS Wales and Public Health bodies,” Owen Pugsley told Healthcare Today, adding that specialist urological consultants and nurses monitor conversations behind the scenes.
Computer Models for Diagnosis
Medical researchers designed a new computer model to help doctors identify aggressive prostate cancer earlier, sparing low-risk patients from unneeded biopsies and treatments, The Independent reported. The £1.4 million initiative, known as Reimagine, will evaluate medical information from over 1,000 patients diagnosed with the condition.
As reported by The Independent and Cheshire Live, the trial will commence on December 10 under the direction of Professor Mieke Van Hemelrijck from King’s College London, working alongside specialists at University College London, Imperial College London, and Radboud University. The project links patient data to NHS information to track how the disease develops over time.
“One of the biggest ongoing challenges in prostate cancer is that we still can’t reliably predict which cancers will become life-threatening and which will remain low risk,” Van Hemelrijck said.
Survivor Perspectives and Future Trials
Barry O’Carroll described his diagnosis as feeling like a ticking time bomb because doctors could not initially determine how aggressive his cancer was, Cheshire Live reported. Placed on active surveillance, his cancer was spotted and removed nine months later when it began to grow.

Dr Matthew Hobbs, Director of Research at Prostate Cancer UK—which funds the trial alongside the John Black Charitable Foundation—stated that the diagnostic tool could bring prostate cancer diagnosis into the 21st century, Cheshire Live reported. Prostate Cancer UK is also conducting the Transform trial to examine effective screening methods.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Worth a look